Dose-finding and pharmacological study of ifosfamide in combination with paclitaxel and carboplatin in resistant small-cell lung cancer

Annals of Oncology

Volumn 12, Issue 6, 2001, Pages 787-792

  Van Putten, J W G ^a   Kerbush, T ^b   Smit, E F ^c   Van Rijswijk, R ^d   Beijnen, J H ^b   Sleijfer, D T ^a   Groen, H J M ^c  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Carboplatin; Ifosfamide; Paclitaxel; Phase 1 study; Small cell lung cancer

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; PACLITAXEL;

ADULT; AGED; ARTHRALGIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIARRHEA; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG CLEARANCE; DRUG HALF LIFE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LUNG SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MULTIDRUG RESISTANCE; MYALGIA; NAUSEA AND VOMITING; PARESTHESIA; PRIORITY JOURNAL; SURVIVAL TIME; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SMALL CELL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IFOSFAMIDE; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PACLITAXEL; THROMBOCYTOPENIA;

EID: 0034948111     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011101026135     Document Type: Article

References (27)

1. Chemotherapy of lung cancer
2. Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy
3. Testing the possible non-cross resistance of two equipotent combination chemotherapy regimens against small-cell lung cancer: A phase II study of the EORTC Lung Cancer Cooperative Group
4. A phase II study of carboplatin and vincristine in previously treated patients with small-cell lung cancer
5. Second-line chemotherapy and its evaluation in small cell lung cancer
6. A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer
7. Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: A non-cross-resistant schedule
8. Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: A Hoosier Oncology Group study
9. The multidrug resistant phenotype in clinical practice; evaluation of cross resistance to ifosfamide and mesna after VP16-213, doxorubicin and vincristine (VPAV) for small cell lung cancer
10. Paclitaxel (Taxol)/ifosfamide-based chemotherapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
11. Paclitaxel, ifosfamide, and carboplatin for the treatment of stages IIIB and IV non-small cell lung cancer: Preliminary results
12. Prediction of carboplatin clearance from standard morphological and biological patient characteristics
13. The determination of 2-and 3-dechloroethylifosfamide in plasma and urine
14. High-performance liquid chromatographic determination of stabilized 4-hydroxy-ifosfamide in human plasma and erythrocytes
15. Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM
16. A review of the pharmacokinetics and pharmacodynamics of combination carboplatin/paclitaxel
17. Considerations regarding the less-than-expected thrombocytopenia encountered with combination paclitaxel/carboplatin chemotherapy
18. Phase I and pharmacologic study of sequences of paclitaxel and cyclophosphamide supported by granulocyte colony-stimulating factor in women with previously treated metastatic breast cancer
19. Phase I study of paclitaxel in combination with cyclophosphamide and granulocyte colony-stimulating factor in metastatic breast cancer patients
20. Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours
21. Ifosfamide metabolism and pharmacokinetics
22. High-dose ifosfamide for soft tissue sarcomas: Set the scene, or senescence?
23. Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: A feasibility study
24. Selective biotransformation of Taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8
25. Phase I trial of weekly paclitaxel in advanced lung cancer
26. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function
27. Nephrotoxicity of ifosfamide - Moving towards understanding the molecular mechanisms